BioCardia to Present Late-Breaking CardiAMP HF Trial Data at THT Meeting
Event summary
- BioCardia's CardiAMP HF trial echocardiography data accepted for late-breaking oral presentation at the Technology and Heart Failure Therapeutics (THT) Meeting on March 2, 2026.
- Presentation by Dr. Amish Raval, Professor of Medicine at UW School of Medicine and Public Health and CardiAMP HF Trial National Co-Principal Investigator.
- CardiAMP Cell Therapy has FDA Breakthrough designation and is reimbursed by CMS.
- BioCardia's CardiAMP Cell Therapy aims to increase capillary density and reduce tissue fibrosis in heart failure patients.
The big picture
BioCardia's presentation of late-breaking data from the CardiAMP HF trial comes at a critical juncture for cellular therapies in cardiovascular disease. The FDA Breakthrough designation and CMS reimbursement highlight the strategic importance of this therapy in addressing a significant unmet need in heart failure treatment. The results could influence the broader adoption of autologous cell therapies in cardiovascular care.
What we're watching
- Clinical Efficacy
- How the echocardiography results will impact the perceived efficacy of CardiAMP Cell Therapy in treating heart failure.
- Regulatory Pathway
- Whether the positive data will accelerate FDA approval or expand reimbursement options.
- Market Adoption
- The pace at which CardiAMP Cell Therapy could be adopted by healthcare providers if the trial results are favorable.
Related topics